Sanofi (SNY) Cost of Revenue (2009 - 2026)

Sanofi (SNY) has 18 years of Cost of Revenue data on file, last reported at $3.7 billion in Q1 2026.

• Quarterly Cost of Revenue rose 20.89% year-over-year to $3.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.1 billion (up 35.71% YoY) and the FY2025 annual result came in at $15.2 billion, up 7.65% from the prior year.
• Cost of Revenue fell to $3.7 billion in Q1 2026 per SNY's latest filing, from $15.2 billion in the prior quarter.
• The five-year high for Cost of Revenue was $15.2 billion in Q4 2025, with the low at $3.0 billion in Q1 2025.
• Average Cost of Revenue over 5 years is $6.5 billion, with a median of $3.7 billion recorded in 2026.
• Year-over-year, Cost of Revenue surged 251.48% in 2022 and dropped 9.31% in 2024.
• Sanofi's Cost of Revenue stood at $14.0 billion in 2022, then declined by 2.76% to $13.6 billion in 2023, then increased by 3.86% to $14.1 billion in 2024, then gained by 7.65% to $15.2 billion in 2025, then plunged by 75.81% to $3.7 billion in 2026.
• Business Quant data shows SNY's Cost of Revenue at $3.7 billion in Q1 2026, $15.2 billion in Q4 2025, and $10.9 billion in Q3 2025.